Drug intelligence / Profile preview

Washington Univ. School of Medicine S1PR2 compound (±)-5d

Development stage: Unknown
Lead developer: Washington University School of Medicine

Overview

Washington Univ. School of Medicine S1PR2 compound (±)-5d: sourced facts only. name: "A racemic carboxylic acid and its enantiomeric isomers, (±)-5d, (-)-5d, (+)-5d, and 3-fluoropropoxyl analogues 5e, and (±)-5f are potent with IC50 values of 33.4, 13.4, 12.1, 27.7, and 16.4 nM for S1PR2, respectively." [PMID:41448024]; target: "A racemic carboxylic acid and its enantiomeric isomers, (±)-5d, (-)-5d, (+)-5d, and 3-fluoropropoxyl analogues 5e, and (±)-5f are potent with IC50 values of 33.4, 13.4, 12.1, 27.7, and 16.4 nM for S1PR2, respectively." [PMID:41448024]; developer: "Department of Radiology, Washington University School of Medicine, St. Louis, MO 63110, United States." [PMID:41448024]

Targets

S1PR2 (S1P receptor 2)

Beyond the preview

Go deeper on Washington Univ. School of Medicine S1PR2 compound (±)-5d.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Washington Univ. School of Medicine S1PR2 compound (±)-5d.